The reported preliminary net sales for Q4 and the total sales since the launch of Vowst are likely to be viewed positively by investors, indicating strong market adoption and revenue growth for Seres Therapeutics. The gross-to-net reduction is a common occurrence in the pharmaceutical industry and is unlikely to overshadow the positive sales figures. The high number of patient enrollments and new patient starts further supports the potential for continued growth, which could lead to a positive short-term impact on MCRB's stock price.